AI Summary
The article discusses a study that highlights tumor-induced B cell changes in the blood and bone marrow of triple negative breast cancer patients. The research identifies two distinct patterns of B cell abnormalities that could potentially be used as blood biomarkers to predict the response to standard chemotherapy and immunotherapy. This discovery could aid in personalized treatment strategies for triple-negative breast cancer patients.
Researchers have discovered new insights into tumor-induced B cell changes in blood and bone marrow of triple negative breast cancer patients. The findings show two distinct patterns of B cell abnormalities that could serve as blood biomarkers for determining likelihood of response to standard-of-care chemotherapy and immunotherapy.